Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cuvitru for Secondary Immunodeficiency in Rituximab-Treated NHL
NCT03211065Phase 3Completed
- Sponsor
- Rochester General Hospital
- Start
- Jul 2017
- Primary completion
- Nov 2019
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of polyvalent human immunoglobulin in secondary immunodeficiency (SID), sponsored by Rochester General Hospital. Primary endpoint: Number of non-neutropenic infections per subject requiring antibiotics at 1 year. Started Jul 2017; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
secondary immunodeficiency (SID)
Beyond the preview
Go deeper on NCT03211065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03211065.